Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 10Small Cell Lung Carcinoma 5Sarcoma 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Mesothelioma, Malignant 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Pleural Effusion, Malignant 2Ovarian Neoplasms 2Melanoma 2Kidney Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER 1Pathologic Complete Response 1Parathyroid Neoplasms 1Osteosarcoma 1NSCLC 1Multiple Myeloma 1Mesothelioma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Docetaxel 6Gemcitabine 3Carboplatin 3lorlatinib 2cemiplimab 2Vinorelbine 2S 1 (combination) 2Pemetrexed 2Erlotinib Hydrochloride 2Cisplatin 2Cetuximab 2zimberelimab 1surufatinib 1sintilimab 1quemliclustat 1pemigatinib 1pembrolizumab 1nimotuzumab 1fludarabine 1WW Domain-Containing Oxidoreductase 1Paclitaxel 1Interleukin-2 1Gene Expression Profiling 1Drug Therapy 1Cyclophosphamide 1Capecitabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non-Small Cell Lung Cancer × Bortezomib × Thoracic × Clear all
NCT00064636 2005-06-24

Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Millennium Pharmaceuticals, Inc.

Phase 1 Terminated
46 enrolled
Other solid neoplasmThoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡